NANO Nuclear Energy Signs Memorandum of Understanding with Everstar AI to Leverage its Suite of New AI Tools to Modernize the Nuclear Regulatory & Licensing Process Read more
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more